EPILEPSY

  • Screening of antiepileptic drugs : PTZ-assay in the mice

    Epilepsy is a disease characterized by recurrent seizures and it is affecting more than sixty million people worldwide. Available treatments can only partially control the disease and are associated with severe side effects, and the search for more effective and safer drug at controlling seizures therefore remains a crucial challenge for Pharmaceutical industry.
    Pentylenetetrazole (PTZ) –induced seizures in mice is an accepted in-vivo models for the screening of antiepileptic drugs. Seizures are induced by administration of 100 mg/kg, s.c. PTZ (60 min observation period).

  • Compound testing


    Anticonvulsant drugs are usually tested in this model but other treatments could also be considered.
    Please feel free to contact us to discuss the feasibility of your study.
  • Endpoints


    Latency to clonic seizures
    Latency to tonic seizures
    Protection against seizure-induced death

Samples data : compound testing addresses the effect of acute treatment of CD-1 mice, typically injected 30-60 min before the PTZ assay.

  • Keppra® induces a significant delay in the appearance of clonic seizures in mice.

  • Keppra® induces a significant delay in the appearance of tonic seizures in mice.

  • Keppra® significantly reduces
    seizures-induced death in mice.